Literature DB >> 23850943

Adenosine signaling in airways: toward a promising antiasthmatic approach.

Carla Cicala1, Armando Ialenti.   

Abstract

Adenosine participates to asthma physiopathology by signaling through more than just one receptor subtype. Defining the role of each receptor is complicated by evidence that often results obtained on rodents do not coincide with human studies, but what emerges is that an important condition to establish hyperresponsiveness to adenosine in any species of sensitized animals is the exposure to allergen; this feature appears to be very similar to the human situation, since allergic humans regularly undergo exposure to allergen. Furthermore, A₂B in humans, but A₃ receptor in rodents, would mediate, indirectly, the bronchoconstriction in response to adenosine and would play the main role in adenosine-induced airway inflammation and airway hyperreactivity. On the other hand, A₁ receptor over-expressed on asthmatic airways would mediate a direct adenosine bronchoconstrictor effect. Antagonists and agonists to adenosine receptors have been considered as antiasthmatic drugs but often their development has been limited by unwanted effects. Preventing adenosine accumulation in airways should be considered as a novel promising antiasthmatic strategy.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine; Airway; Asthma; CD39; CD73; Hyperreactivity

Mesh:

Substances:

Year:  2013        PMID: 23850943     DOI: 10.1016/j.ejphar.2013.06.033

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues.

Authors:  Tianyu He; Egidio Brocca-Cofano; Delbert G Gillespie; Cuiling Xu; Jennifer L Stock; Dongzhu Ma; Benjamin B Policicchio; Kevin D Raehtz; Charles R Rinaldo; Cristian Apetrei; Edwin K Jackson; Bernard J C Macatangay; Ivona Pandrea
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

Review 2.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

3.  Lack of Ecto-5'-Nucleotidase Protects Sensitized Mice against Allergen Challenge.

Authors:  Elisabetta Caiazzo; Ida Cerqua; Roberta Turiello; Maria Antonietta Riemma; Giacomo De Palma; Armando Ialenti; Fiorentina Roviezzo; Silvana Morello; Carla Cicala
Journal:  Biomolecules       Date:  2022-05-13

4.  Exacerbation of Allergic Airway Inflammation in Mice Lacking ECTO-5'-Nucleotidase (CD73).

Authors:  Elisabetta Caiazzo; Ida Cerqua; Maria Antonietta Riemma; Roberta Turiello; Armando Ialenti; Jurgen Schrader; Giuseppe Fiume; Carmen Caiazza; Fiorentina Roviezzo; Silvana Morello; Carla Cicala
Journal:  Front Pharmacol       Date:  2020-11-30       Impact factor: 5.810

5.  Allosterism vs. Orthosterism: Recent Findings and Future Perspectives on A2B AR Physio-Pathological Implications.

Authors:  Elisabetta Barresi; Claudia Martini; Federico Da Settimo; Giovanni Greco; Sabrina Taliani; Chiara Giacomelli; Maria Letizia Trincavelli
Journal:  Front Pharmacol       Date:  2021-03-24       Impact factor: 5.810

6.  Inactivation of AUF1 in Myeloid Cells Protects From Allergic Airway and Tumor Infiltration and Impairs the Adenosine-Induced Polarization of Pro-Angiogenic Macrophages.

Authors:  Sofia Gargani; Niki Lourou; Christina Arapatzi; Dimitris Tzanos; Marania Saridaki; Esmeralda Dushku; Margarita Chatzimike; Nikolaos D Sidiropoulos; Margarita Andreadou; Vasileios Ntafis; Pantelis Hatzis; Vassiliki Kostourou; Dimitris L Kontoyiannis
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

7.  Purinergic Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Zongye Cai; Ly Tu; Christophe Guignabert; Daphne Merkus; Zhichao Zhou
Journal:  J Am Heart Assoc       Date:  2020-09-01       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.